Stephen Glover

Company: ZyVersa Therapeutics

Job title: Chief Executive Officer

Seminars:

Strategic Prioritization of Inflammatory Indications: Navigating Risk, Reward & Clinical Feasibility 3:30 pm

Analyzing the trade-offs between orphan inflammatory indications vs larger markets with complex disease heterogeneity Reviewing how disease prevalence and competitive activity influences early pipeline decisions Unlocking real-world examples on how strategic indication shifts impact drug development opportunitiesRead more

day: Conference Day One PM